

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

②

It is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and reviewing the collection of information, Send comments regarding this burden estimate or any other aspect of this collecting this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Road to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

AD-A231 197

2 REPORT DATE
19893 REPORT TYPE AND DATES COVERED
Reprint

(see title on reprint)

6 AUTHOR(S)

Landauer et al.

5 FUNDING NUMBERS

Program Element No.
NWED QAXMWork Unit No.
00159 and 00162

7 PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

Armed Forces Radiobiology Research Institute
Defense Nuclear Agency
Bethesda, MD 20889-51458 PERFORMING ORGANIZATION
REPORT NUMBER

SR90-33

9 SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)

Defense Nuclear Agency
Washington, DC 2030510 SPONSORING/MONITORING
AGENCY REPORT NUMBER

11 SUPPLEMENTARY NOTES

DTIC
ELECTE
JAN 22 1991
S E D

12a. DISTRIBUTION/AVAILABILITY STATEMENT

Approved for public release; distribution unlimited.

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 words)

Accession For

NTIS GRA&I

DTIC TAB

Unannounced

Justification

By

Distribution/

Availability Codes

Dist

Avail and/or
Special

A-1 20

14 SUBJECT TERMS

15. NUMBER OF PAGES

6

16. PRICE CODE

17. SECURITY CLASSIFICATION
OF REPORT

UNCLASSIFIED

18. SECURITY CLASSIFICATION
OF THIS PAGE

UNCLASSIFIED

19. SECURITY CLASSIFICATION
OF ABSTRACT20. LIMITATION OF
ABSTRACT

PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS

Prostaglandins Leukotrienes and Essential Fatty Acids (1990) 39, 247-252
© Longman Group UK Ltd 1990

0952-3278/90/0039-0247/\$10.00

ARMED FORCES RADIOBIOLOGY
RESEARCH INSTITUTE
SCIENTIFIC REPORT
SR90-33

Behavioral and Physiological Effects of Leukotriene C₄

M. R. Landauer*, H. D. Davis* and T. L. Walden†

Departments of Behavioural Sciences and Radiation Biochemistry†, Armed Forces Radiobiology Research Institute, Bethesda, MD 20814-5145, USA (Reprint requests to MRL)*

ABSTRACT. Leukotriene C₄ (LTC₄), a lipoxygenase metabolite of arachidonic acid, is a biological mediator of vasoregulation, pulmonary activity, shock, and inflammation, that has been demonstrated to have radioprotective efficacy. The effects of LTC₄ on locomotor activity, rectal temperature and hematocrit were examined. Subcutaneous administration of doses of 1.0 µg LTC₄/mouse or less did not affect locomotor activity. Doses of 5 or 10 µg LTC₄/mouse, however, resulted in almost complete cessation of locomotion within 12-14 min following treatment. At these doses, activity was suppressed for 2 h with complete recovery by 3 h postinjection. While a dose as high as 10 µg LTC₄ did not affect rectal temperature, 5 and 10 µg LTC₄ resulted in hematocrit increases of 10% and 40% respectively. Hematocrit returned to baseline within 1 h after a 5 µg pretreatment of LTC₄, and by 3 h following a 10 µg pretreatment. The duration of LTC₄-induced locomotor suppression did not correlate with previously determined durations of LTC₄-induced radioprotection.

INTRODUCTION

The leukotrienes have emerged as an important class of biological mediators, although little information is available regarding their effects on behavioral processes. They have physiological roles in vasoregulation (1-7), neurotransmission (8, 9), hormonal regulation (9, 10), smooth muscle contraction (9, 11), and may also participate in inflammatory processes (9, 12), anaphylactic shock (9, 11) and asthma (9, 13). The peptide leukotrienes are derived from arachidonic acid through the lipoxygenase pathway and consist of leukotrienes (LT) C₄, D₄, and E₄. Some biological activities attributed to LTC₄ may be indirect through its conversion to LTD₄ or LTE₄. Each of these compounds is biologically active and generally elicits biological responses through interaction with specific receptors on the cell surface of the target tissue (14). Some biological activities are induced directly by LTC₄. Others may be mediated its conversion to LTD₄ or LTE₄. Activation of the receptor sometimes initiates synthesis of other eicosanoids or biological mediators (9, 11, 12). Unlike prostaglandins (15), leukotrienes are not

capable of crossing the blood/brain barrier (16), although they may be synthesized by brain tissue (12, 17).

Responses to eicosanoids may vary from tissue to tissue and between species. LTC₄, for example, results in vasodilation and increased blood flow in the skin of humans (7), but is vasoconstrictive in the dog coronary artery (18, 19). Direct administration of LTC₄ into the brain has been shown to alter behavior in rats (20).

LTC₄ has recently been shown to protect V79AO3 Chinese hamster fibroblasts in culture (21), and mouse hematopoietic stem cells in vivo from damage by ionizing radiation (22). It also enhances the survival of mice exposed to an otherwise lethal dose of gamma radiation (23). Leukotriene treatment must be administered prior to irradiation to elicit protection (22, 23). In mice, optimal radioprotection of hematopoietic stem cells is induced by LTC₄ treatment 5-15 min before radiation exposure. A pretreatment of 10 µg LTC₄ per mouse provides a dose reduction factor (DRF) of 1.6 for exogenous spleen colony forming units (CFU-S), and a DRF of 2.0 for granulocyte macrophage progenitor stem cells (22).

Radioprotectors are advantageous for both civil defense and clinical use. In a civil defense setting, agents that maximize protection from radiation in-

jury with minimal suppression of behavior are required. In the clinic, behavioral side effects are less critical, and compounds that selectively protect normal tissues can be used to enhance the therapeutic efficacy of radio- and chemotherapy.

Because of the important biological roles and the significant radioprotection afforded by LTC₄ (22), we have investigated the time course of some behavioral and physiological responses of this compound. In this paper we describe the effects of subcutaneous administration of LTC₄ on locomotor behavior. Further, because LTC₄ is known to affect body temperature (20) and hematocrit (5) in rats, these parameters were monitored to determine if alterations in behavior were associated with these measures.

MATERIALS AND METHODS

Subjects

Male CD2F₁ male mice, 10–12 weeks old (20–25 grams) were obtained from Charles River Breeding Laboratory (Raleigh, NC). They were quarantined on arrival and representative animals were screened for evidence of disease. Mice were housed in groups of 8–10 in Micro-Isolator cages on hardwood chip contact bedding in an AAALAC accredited facility. Rooms were maintained at 21 ± 1°C with 50% relative humidity on a reversed 12–12 hr light-dark cycle with lights off at 2 pm. Commercial rodent chow (Wayne Rodent Blox) and acidified water (pH, 2.5) were freely available. All mice were euthanized by inhalation of carbon dioxide at the end of the experiment.

Drug

LTC₄ was the generous gift of Dr. J. Rokach (Merck-Frosst Laboratories, Pointe Claire-Dorval, Canada). It was dissolved in physiological saline, and administered to mice subcutaneously (s.c.) in the nape of the neck in a volume of 100 µl. Each animal received a single injection of either the saline vehicle or 0.1, 1, 5 or 10 µg LTC₄ (N = 9–10/group).

Locomotor activity measurement

A computerized Digiscan Animal Activity Monitor (Model RXYZCM-16, Omnitech Electronics, Columbus, Ohio) was used to quantitate locomotor behavior. This system has been previously used to monitor the effects of a number of radioprotective agents on locomotor activity, including prostaglandins (24, 25). Briefly, the apparatus used an array of infrared photodetectors spaced 2.5 cm apart to determine total distance travelled (horizontal activity; ambulation) and vertical sensors to record the

number of vertical movements (vertical activity; rearing). The test chamber consisted of a 20 × 20 × 30.5 cm Plexiglas arena. The horizontal and vertical detectors were positioned 1.3 and 6.3 cm, respectively, above the floor of the arena.

Immediately following injection of LTC₄, animals were placed into the activity monitor where horizontal and vertical activity were recorded every 2 min for 1 h to ascertain the behavioral onset of the drug. Thereafter, activity was recorded at 1 h intervals for the next 2 h, after which time all groups had returned to control levels. All testing took place during the dark portion of the light-dark cycle. After each test, the apparatus was cleaned with a 50% alcohol solution.

Temperature measurement

Rectal temperatures were monitored using a Thermistar Thermometer (Model 8110-20, Cole-Parmer, Chicago, IL) thermister probe (Model #423, Yellow Springs Instruments, Yellow Springs, OH). The probe was inserted 2 cm into the rectum and secured in place to the tail by a 2.5 cm strip of adhesive tape. It remained in place during the 3 h measurement period during which time the mice were restrained. The study was conducted in an environmentally controlled room set at 22°C. Mice received either s.c. injection of the saline vehicle (N=7) or 10 µg LTC₄ (N=7). The rectal temperature was recorded every 5 min for the first hour and at 30 min intervals for the next 2 h.

Hematocrit

Animals received a s.c. injection of 0 (saline vehicle), 0.1, 1.0, 5.0, or 10.0 µg LTC₄ in saline (N=5–17/group). Mice were anesthetized with methoxyflurane (Pitman-Moore, Inc., Washington Crossing, N.J.) and blood samples for hematocrit determinations were obtained from the retro-orbital sinus. Measurements were made in duplicate and each animal was bled only once, at 0, 10, 60, or 120 min following LTC₄ treatment.

Statistical analysis

One-way analysis of variance was used to determine significance levels for the effects of LTC₄ on locomotor activity and rectal temperature. Post hoc comparisons were made using Dunnett's test. Mean values of the hematocrit were compared to the control group using Student's t-tests.

RESULTS

Locomotor activity

LTC₄ produced a dose-dependent decrease in

locomotor activity. Doses of 0.1 and 1.0 μg did not significantly alter locomotor behavior compared to control values. Doses of 5.0 and 10.0 μg , however, resulted in pronounced reductions in locomotion. At these dosages, both ambulation and rearing were significantly reduced from control values within 6 min of injection and maximal effect (a decrement of 95–100%) was observed at 12–14 min. During the second hour, postinjection locomotor activity was approximately 50% of controls. All animals fully recovered locomotor performance by the third hour following drug administration. Since the time course and magnitude of the response for both horizontal and vertical activity were very similar, only one parameter (vertical activity) is illustrated in Figures 1 and 2.




Fig. 1 Time course of leukotriene C₄ as a function of dose on vertical activity (rearing) during the first 60 min after injection (N= 9–10/group). Activity counts are presented in 2 min intervals. LTC₄ was administered subcutaneously immediately prior to assessment of locomotor activity. Maximal effect was reached 12–14 min postinjection. Similar results were obtained for horizontal activity (data not shown).




Fig. 2 Duration of action of the effects LTC₄ on vertical activity (rearing). By 3 h postinjection all groups had returned to control levels (N= 9–10/group). Horizontal activity showed a similar pattern of recovery (data not shown). **Significantly ($p < 0.01$) from vehicle control group.

Rectal temperature

There were no significant differences in the rectal temperature of mice treated with saline or 10 μg LTC₄ (Fig. 3). The temperature of both the control and LTC₄ treated mice decreased as a function of time and is likely related to the duration of restraint.

Hematocrit

A dose-dependent increase in the hematocrit was observed in animals receiving LTC₄ (Table). Although no change in hematocrit was observed following doses of 0.1 or 1.0 $\mu\text{g}/\text{mouse}$, administration of 5.0 and 10.0 μg LTC₄ resulted in a 10% and 40% increase compared to controls, at 10 min postinjection. At 1 h after drug administration the 5.0 μg group had returned to control levels. Mice receiving 10.0 μg still had a 10% elevation in hematocrit at 2 h postinjection, and returned to normal by the third hour following treatment.

DISCUSSION

Doses of LTC₄ which have previously been shown to be radioprotective (5 to 10 μg LTC₄/mouse which is equivalent to 200 to 400 $\mu\text{g}/\text{kg}$ body weight) (22, 23) resulted in a rapid reduction in locomotor activity and significant increases in the hematocrit, although rectal temperature remained unaffected. The decrease in locomotor behavior was dose dependent. While doses of 1 μg or less did not alter locomotor activity, administration of 5 and 10 μg LTC₄ resulted in almost total cessation of ambulation and rearing within 10–15 min after single s.c. injection. The animals did not fully recover from this reduction in activity until 3 h post-injection. Although this is the first study to report the effects of




Fig. 3 Effect of LTC₄ (10 µg/mouse) on rectal temperature, expressed as the change in temperature from baseline levels taken 15 min prior to drug administration. There were no significant differences between the control mice and the LTC₄ group at any during the 3 h recording period (N=7/group).

Table Effect of LTC₄ on hematocrit

| ug LTC ₄ per mouse | 10 min | Time Post-Treatment 60 min | 120 min | 180 min |
|----------------------------------|-----------------|-------------------------------|-----------------|--------------|
| 0.0 | 49.6 +/- 0.4 | — | — | — |
| 0.1 | 48.8 +/- 0.4 | 48.5 +/- 0.6 | — | — |
| 1.0 | 50.0 +/- 0.1 | 48.3 +/- 0.5 | — | — |
| 5.0 | 55.0 +/- 0.3*** | 48.6 +/- 1.1 | — | — |
| 10.0 | 69.6 +/- 1.4*** | 63.0 +/- 1.9*** | 54.8 +/- 1.3*** | 50.2 +/- 1.3 |

*** significantly different from control, $p < 0.0001$, t-test (N = 5–17/group)

s.c. administration of LTC₄ on locomotor behavior in mice, Brus et al (20) found that intracerebroventricular (ICV) administration of 1 µg of this compound to rats produced locomotor deficits that were apparent at 1 and 30 min after injection but not at 1 h. No decrease in locomotor activity was observed in mice in the present study following s.c. administration of 1 µg LTC₄.

Other eicosanoids such as prostaglandins of the E series result in a similar suppression of locomotor activity of rats (26), and we have recently described (24, 25) the decrease in locomotor behavior of mice treated with 16,16-dimethyl prostaglandin E₂ (DiPGE₂). Pretreatment with 40 µg/mouse DiPGE₂ provided a dose reduction factor (DRF) of 1.72 for animal survival following gamma irradiation (27). DiPGE₂ reduction of locomotor activity was dose dependent and required up to 30 h after administration of 40 µg/mouse to return to normal.

The decrease in ambulation and rearing by LTC₄ is comparable to that observed for 200 mg/kg of WR-2721, a thiol radioprotective agent with a DRF at this dose of approximately 1.6 (28–30). Although LTC₄ contains a thiol ether, the radioprotective action is not believed to act by a thiol free radical scavenging mechanism (22). In terms of radioprotective efficacy, five times more en-

dogenous spleen colonies (E-CFU) survive irradiation when animals are pretreated with 10 µg LTC₄ than for mice receiving equivalent doses of LTD₄ or LTE₄ (22). This indicates that the radioprotection is attributable to the effects of LTC₄ rather than its conversion to LTD₄ or to LTE₄. The extent to which LTC₄ mediated behavioral effects may be due to other leukotrienes has yet to be determined.

Subcutaneous administration of doses of LTC₄ (10 µg) that induced radioprotection (22), reduced locomotor activity, and elevated the hematocrit, did not significantly affect rectal temperature. A similar lack of temperature response was observed in rats receiving 1 µg LTC₄ by ICV (31) or intrapreoptic administration (32). A decrease in body temperature, however, was observed in rats 10 min following an ICV injection of 7.5 µg LTC₄ (20). Possible effects of leukotrienes on temperature elevation have been implied from LTC₄ measurements in tissue biopsies of women with dysmenorrhea (33).

Although LTC₄ can be produced by nerve tissue (9, 17) and act as a neurotransmitter (8), it is not capable of crossing the blood/brain barrier (16). Therefore, it is unlikely that the rapid onset in suppression of locomotor behavior is the result of a

direct action on the central nervous system. The decreased activity observed in the present study may either result from intermediate messengers produced by the leukotriene, or in response to the physiological action of LTC₄. Some physiological responses to leukotrienes are mediated by inducing synthesis of other eicosanoids, such as thromboxanes and prostaglandins (11) that in turn produce the biological response. Prostaglandins are known to cross the blood/brain barrier (15) and to suppress locomotor activity (24–26).

Leukotrienes have direct potent activity on constriction of tracheal and bronchial smooth muscle (9, 11) and also vasoactivity (1, 4, 7, 17). Within 10 min after treatment with doses of LTC₄ that produced a behavioral decrement (5 and 10 µg/mouse), hematocrit levels had increased by at least 10% and 40% respectively. Increases in hematocrit and mean arterial blood pressure have been reported previously following intravenous administration of LTC₄ to rats (5, 6). Moreover, LTC₄ is known to promote plasma leakage from the vasculature (1). The short latency for the reduction in locomotor activity may reflect the rapid physiological responses induced by LTC₄. A 10% or greater elevation in hematocrit would likely increase resistance to blood flow, in turn reducing oxygen delivery. LTC₄ has been previously shown to decrease coronary flow (18, 19) with a concomitant reduction in contractile force (34). A reduction of blood flow to the heart could affect locomotor activity, although we have not determined if LTC₄ induces vasoconstriction of mouse coronary arteries. However, a decrease in the quantity of blood obtained from mice by cardiac puncture was observed at times corresponding to the increase in hematocrit and optimal period for radioprotection following administration of LTC₄ (T. L. Walden, Jr., unpublished).

Maintenance of the duration of the locomotor decrement does not appear to be associated with the physiological responses producing the hematocrit elevation. With 5 µg LTC₄, locomotor behavior was reduced by 88% within 1 h and 50% by 2 h post-treatment (Fig. 2). In a parallel study (Table), the hematocrit, after 5 µg LTC₄, had returned to normal within 1 h. In addition, the duration of the radioprotective action of LTC₄ (22) does not follow the same time course as that found for the suppression of locomotor behavior. Administration of 10 µg LTC₄ 5–15 min prior to radiation exposure resulted in optimal radioprotection to mouse hematopoietic stem cells. At this dose, the protective activity was lost by 90 min post-treatment (22), while locomotor activity did not return to control level until 3 h after LTC₄ administration.

The toxic effects of radioprotectors are well established and occur at both the cellular and tissue

levels (35). We have observed that the onset of behavioral toxicity as measured by locomotor activity decrements corresponds to the optimal pre-radiation treatment time for a variety of radioprotective compounds including LTC₄ (this study), DiPGE₂ (24, 25), WR-2721 (28–30) and glucan (36). The duration of the radioprotective effect for each of these is shorter than the behavioral decrement. We are continuing to explore the use of the locomotor activity test as an effective means to predict the optimal pre-radiation time for administration of radioprotectant compounds.

It may also be possible to mitigate the behavioral toxicity of LTC₄ without altering its radioprotective properties. This could be accomplished by co-administration of LTC₄ with agents that reverse the behavioral disruption. Alternatively, it may be feasible to develop LTC₄ analogs that retain the radioprotective or other clinically beneficial properties without the production of concomitant behavioral side-effects. In addition, it is likely that a mixture of radioprotective agents that act by different mechanisms will be required to provide a radioprotective compound that will offer effective protection from ionizing radiation with minimal toxicity.

Acknowledgements

We thank M. E. Cranford, N. K. Farzaneh and M. E. Faccioli for their assistance during this experiment. Portions of this work were presented at the 37th annual meeting of the Radiation Research Society, Seattle, WA in March 1989. This research was supported by the Armed Forces Radiobiology Research Institute, Defense Nuclear Agency, under work units 00159 and 00162. The views presented in this paper are those of the authors; no endorsement by the Defense Nuclear Agency has been given or should be inferred. Research was conducted according to the principles enunciated in the 'Guide for the Care and Use of Laboratory Animals' prepared by the Institute of Laboratory Animal Resources, National Research Council.

References

1. Dahlen S-E, Bjork J, Hedqvist P, Arfors K-E, Hammarstrom S, Lindgren J A, Samuelsson B. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: *In vivo* effects with relevance to the acute inflammatory response. *Proceedings of the National Academy of Sciences (USA)* 78: 3887–3891, 1981.
2. Lipton H L, Armstead W M, Hyman A L, Kadowitz P J. Vasoconstrictor effects of leukotrienes C₄ and D₄ in the feline mesenteric vascular bed. *Prostaglandins* 27: 233–243, 1984.
3. Malik A B, Perlman M B, Cooper J A, Noonan T, Bizios R. Pulmonary microvascular effects of arachidonic acid metabolites and their role in lung vascular injury. *Federation Proceedings* 44: 36–42, 1985.
4. Berkowitz B A, Zabko-Potapovich B, Valocik R, Gleason J G. Effects of the leukotrienes on the vasculature and blood pressure of different species. *Journal of Pharmacology and Experimental Therapeutics* 229: 105–112, 1984.
5. Badr K F, Baylis C, Pferrer J M, Pfeffer M A,

- Soberman R J, Lewis R A, Austen K F, Corey E J, Brenner B F. Renal and systemic hemodynamic responses to intravenous infusion of leukotriene C₄ in the rat. *Circulation Research* 54: 492-499, 1984.
6. Filep J, Foldes-Filep E, Frolich J C. Vascular responses to leukotriene B₄, C₄, and D₄ following FPL 55712, indomethacin, saralasin, phentolamine and verapamil in the conscious rat. *British Journal of Pharmacology* 90: 431-439, 1987.
7. Bisgaard H, Kristensen J, Sondergaard J. The effect of leukotriene C₄ and D₄ on cutaneous blood flow in humans. *Prostaglandins* 23: 797-801, 1982.
8. Palmer M R, Mathews R, Murphy R C, Hoffer B J. Leukotriene C elicits a prolonged excitation of cerebellar Purkinje neurons. *Neuroscience Letters* 18: 173-180, 1980.
9. Samuelsson B, Dahlen S-E, Lindgren J A, Rouzer C A, Serhan C N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. *Science* 237: 1171-1176, 1987.
10. Hulting A L, Lindgren J A, Hokfelt T, Eneroth P, Werner S, Patrono C, Samuelsson B. Leukotriene C₄ as a mediator of luteinizing hormone release from rat anterior pituitary cells. *Proceedings of the National Academy of Sciences (USA)* 82: 3834-3838, 1985.
11. Dahlen S-E, Hedqvist P, Westund P, Granstrom E, Hammarstrom S, Lindgren J A, Radmark O. Mechanisms of leukotriene-induced contractions of guinea pig airways: Leukotriene C₄ has a potent direct action whereas leukotriene B₄ acts indirectly. *Acta Physiologica Scandinavica* 118: 393-403, 1983.
12. Samuelsson B. Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. *Science* 220: 568-575, 1983.
13. Dahlen S-E, Hansson G, Hedqvist P, Bjorck T, Granstrom E, Dahlen B. Allergen challenge of the lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C₄, D₄, and E₄. *Proceedings of the National Academy of Sciences (USA)* 80: 1712-1716, 1983.
14. Robertson R P. Characterization and regulation of prostaglandin and leukotriene receptors: An overview. *Prostaglandins* 31: 395-411, 1986.
15. Wolfe L S, Eiccosanoids: Prostaglandins, thromboxanes, leukotrienes, and other derivatives of carbon-20 unsaturated fatty acids. *Journal of Neurochemistry* 38: 1-14, 1982.
16. Spector R, Goetzl E J. Commentary: The role of concentrative leukotriene transport systems in the central nervous system. *Biochemical Pharmacology* 35: 2849-2853, 1986.
17. Kiwak K J, Moskowitz M A, Levine L. Leukotriene production in gerbil brain after ischemic insult, subarachnoid hemorrhage, and concussive injury. *Journal of Neurosurgery* 62: 865-869, 1985.
18. Wargovich T, Mehta J, Nichols W W, Pepine C J, Conti R. Reduction of blood flow in normal and narrowed coronary arteries of dogs by leukotriene C₄. *Journal of the American College of Cardiology* 6: 1047-1051, 1985.
19. Woodman O L, Dusting G J. Coronary vasoconstriction induced by leukotrienes in the anesthetized dog. *European Journal of Pharmacology* 86: 125-128, 1982.
20. Brus R, Krzeminski T, Juraszcyk Z, Kurcok A, Felinska W, Kozik W. Central effects of leukotriene C₄ and D₄ in rats and mice. *Biomedica Biochimica Acta* 45: 1153-1158, 1986.
21. Walden T L Jr, Holahan E V, Catravas G N. Development of a model system to study leukotriene-induced modification of radiosensitivity in mammalian cells. *Lipid Research* 25: 587-590, 1986.
22. Walden T L Jr, Patchen M L, MaoVittie T J. Leukotriene-induced radioprotection of hematopoietic stem cells in mice. *Radiation Research* 113: 388-395, 1988.
23. Walden T L Jr. Pretreatment with leukotriene C₄ enhances the whole-animal survival of mice exposed to ionizing radiation. *Annals of the New York Academy of Sciences* 524: 431-433, 1988.
24. Landauer M R, Walden T L Jr, Davis H D, Dominitz J A. Alterations in locomotor activity induced by radioprotective doses of 16,16-dimethyl prostaglandin E₂. pp 244-251 in *Prostaglandins and Lipid Metabolism in Radiation Injury* (T L Walden Jr, H N Hughes eds) Plenum Press, New York, 1987.
25. Landauer M R, Walden T L Jr, Davis H D. Behavioral effects of radioprotective agents in mice: Combination of WR-2721 and 16,16 dimethyl prostaglandin E₂. *Proceedings of the 21 Annual Meeting of the European Society for Radiation Biology*, in press.
26. Gilmore D P, Shakh A A. The effect of prostaglandin E₂ in inducing sedation in the rat. *Prostaglandins* 2: 143-152, 1972.
27. Walden T L Jr, Patchen M L, Snyder S L. 16,16-Dimethyl prostaglandin E₂ increases survival in mice following irradiation. *Radiation Research* 109: 440-448, 1987.
28. Landauer M R, Davis H D, Dominitz J D, Weiss J F. Dose and time relationships of the radioprotector WR-2721 on locomotor activity in mice. *Pharmacology, Biochemistry and Behavior* 27: 573-576, 1987.
29. Landauer M R, Davis H D, Dominitz J D, Weiss J F. Comparative behavioral toxicity of four sulfhydryl radioprotective compounds in mice: WR-2721, cysteamine, diethyldithiocarbamate, and N-acetylcysteine. *Pharmacology and Therapeutics* 39: 97-100, 1988.
30. Landauer M R, Davis H D, Dominitz J D, Weiss J F. Long-term effects of radioprotector WR-2721 on locomotor activity and body weight of mice following exposure to ionizing radiation. *Toxicology* 49: 315-323, 1988.
31. O'Rourke S T, Rudy T A. Intracerebroventricular and preoptic injections of LTC₄, D₄, and E₄ in the rat: Lack of febrile effect. *Brain Research* 295: 283-288, 1984.
32. Mashburn T A Jr, Llanos-Q J, Ahokas R A, Blatteis C M. Thermal and acute-phase protein responses of guinea pigs to intrapreoptic injections of leukotrienes. *Brain Research* 376: 285-291, 1986.
33. Rees M C, DiMarzo V, Tippins J R, Morris H R, Turnbull A C. Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhoea and menorrhagia. *Journal of Endocrinology* 113: 291-295, 1987.
34. Roth D M, Lefer D L, Hock C E, Lefer A M. Effects of peptide leukotrienes on cardiac dynamics in rat, cat, and guinea pig heart. *American Journal of Physiology* 249: 477-484, 1985.
35. Maisin J R. Protection against ionizing radiation by combinations of radioprotectors. *Pharmacology and Therapeutics* 39: 189-193, 1988.
36. Landauer M R, Patchen M L, Davis H D. Time course of behavioral effects in mice treated with soluble glucan. *Abstracts of the 4th International Conference on Immunopharmacology*, Osaka, Japan, p 91, 1988.